Arkansas Children's

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Duchenne muscular dystrophy3 trials
• Acute lymphoblastic leukaemia1 trial
• Childhood cancers1 trial
• Chronic lymphocytic leukaemia1 trial
• Haemophilia1 trial
• Ulcerative colitis1 trial

Phase

• Phase 32 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Completed2 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial

Lead sponsor

• Arkansas Children's Hospital Research Institute2 trials
• Pfizer2 trials
• Avidity Biosciences, Inc.1 trial
• Sarepta Therapeutics, Inc.1 trial

Running trials

• Recruiting

  A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)

  NCT07582276· Arkansas Children's Hospital Research Institute· Source

  Contact: Carol D Pierce, RN

• Recruiting

  A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

  NCT07422337· Arkansas Children's Hospital Research Institute· Source

  Contact: Stephanie Thomas, RN

• Recruiting

  A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

  NCT05287126· Phase 2· Pfizer· Source

• Active, not recruiting

  Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

  NCT04281485· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Haemophilia1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

  NCT05670730· Phase 1/2· Avidity Biosciences, Inc.· Source

• Completed

  A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05096221· Phase 3· Sarepta Therapeutics, Inc.· Source